AATB Applauds Reintroduction of the Shandra Eisenga Human Cell and Tissue Product Safety Act

AATB commends Representatives John Moolenaar (R-MI) and Debbie Dingell (D-MI) for reintroducing the Shandra Eisenga Human Cell and Tissue Product Safety Act, a vital piece of legislation aimed at preventing tuberculosis (TB) infections linked to tissue transplants.

Join Us in Atlanta for the 2025 AATB Annual Meeting – Submit Your Session Proposals and Abstracts!

Mark your calendars for the 2025 AATB Annual Meeting, which will take place October 12-15, 2025, in Atlanta, GA. This must-attend event will bring together professionals from across the tissue donation and transplantation community to connect, innovate, and advance meaningful progress.

AATB Advocates for Tissue Banking Policy on Capitol Hill

Earlier this week, AATB representatives and members had the incredible opportunity to visit Capitol Hill, to advocate for key issues impacting the tissue banking community.

AATB Eliminates Additional Fees for Satellite Site Inspections

AATB is pleased to announce that we will no longer charge institutional members a supplemental fee for satellite site inspections conducted as part of the routine three-year accreditation cycle. 

FDA Revises Implementation Date for Sepsis and Mtb Guidance

The FDA has announced a revised implementation date of May 4, 2025, for its recently issued guidance documents.

Medicare Coverage Updates on Skin Substitutes

On Friday, January 24, 2025, all seven Medicare Administrative Contractors (MACs) announced a delay in implementing final skin substitute Local Coverage Determinations (LCDs). Initially set to take effect on February 12, 2025, the implementation date has been postponed to April 13, 2025.

Bulletin 25-1

Navigating Regulatory Changes: AATB's Response to the FDA Guidance Documents and Executive Order

In light of recent regulatory developments, it is essential for stakeholders in the tissue banking community to stay informed about potential changes to FDA guidance documents.

Contact Your Congressional Office Regarding FDA Guidance on Tissue Availability

On January 6, 2025, the FDA released six guidance documents, including two final documents: Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by HCT/Ps (Sepsis guidance) and Recommendations to Reduce the Risk of Transmission of Mycobacterium tuberculosis (Mtb) by HCT/Ps (Mtb guidance).

AATB Leads Effort to Address FDA Mtb and Sepsis Final Guidance Documents with Trump Administration HHS Transition Team

AATB has led the drafting of a letter to the Department of Health and Human Services Transition Team for President-elect Donald Trump, joined by AOPO and EBAA, to urge the immediate rescission of two FDA guidance documents released on January 6, 2025.